What Does Auvi-Q Cost in 2026?

Auvi-Q is the brand name of an epinephrine auto-injector made by Kaléo, a privately held Richmond, Virginia specialty pharmaceutical company. The device is about the size of a credit card and speaks step-by-step voice instructions aloud, with a retractable needle that reduces accidental needlestick risk. Auvi-Q is FDA-approved for emergency treatment of life-threatening allergic reactions (anaphylaxis) in three strengths: 0.3 mg for patients 66 pounds and heavier, 0.15 mg for 33 to 66 pounds, and 0.1 mg for infants and toddlers 16.5 to 33 pounds. Each prescription is a 2-pack plus a trainer device. Because patients carry and self-administer Auvi-Q outside a clinic, it is a Medicare Part D drug rather than a Part B drug, and it carries no J-code for pharmacy billing. The Inflation Reduction Act of 2022 did not select epinephrine for Medicare price negotiation, so no Maximum Fair Price applies to Auvi-Q in 2026.

Auvi-Q pricing in 2026 has three layers that patients often confuse. The retail list price at a standard pharmacy counter runs about $762 to $872 for a 2-pack, according to GoodRx and SingleCare 2026 data. Kaléo's direct-delivery route through ASPN Pharmacies, its specialty pharmacy partner, lists a cash price of about $360 for uninsured or non-covered patients, and Kaléo states that patients with high-deductible plans or no Auvi-Q coverage pay no more than $150 through that channel. Commercially insured patients can use the AUVI-Q Support Copay Program to pay $35 or less per fill. That structure is why the page title refers to a direct program: the $0 outcome is real, but it belongs to the income-tested Kaléo Patient Assistance Program, not to every cash buyer. Patients who simply want the cheapest epinephrine auto-injector at the pharmacy counter should also price the Teva generic EpiPen-style device, which is a different product.

Patients comparing Auvi-Q with EpiPen should weigh device preference against price. A generic epinephrine auto-injector approved in 2018 (Teva) is AB-rated to EpiPen, not to Auvi-Q, so a pharmacist cannot substitute a generic for an Auvi-Q prescription without a new prescription from the prescriber. Medicaid programs cover epinephrine auto-injectors in most states with nominal $1 to $4 copays, but a state formulary may prefer a different device and require prior authorization for Auvi-Q. Households comparing income tests can look up the federal poverty level and Medicaid income limits before applying. This page reflects the 2026 HHS poverty guidelines, the 2026 Medicare Part D benefit, and Kaléo program terms as of September 2026.

What Auvi-Q Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same auvi-q can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Auvi-Q is a pharmacy-dispensed, self-carried emergency drug, so most patients never see a hospital charge for the device itself. The hospital cost appears afterward: after anaphylaxis, emergency departments commonly bill epinephrine administration, observation, and facility fees. Chargemaster prices for an epinephrine dose given in the emergency department can range from a few hundred to a few thousand dollars per episode in 2026, because hospitals apply a markup to a low-cost ampule and bundle drug, nursing, and room time into one facility fee. Physician-administered epinephrine is typically billed with HCPCS J0171 (epinephrine, 0.1 mg), which is a different billing pathway from the pharmacy claim for an Auvi-Q 2-pack. If you used your own Auvi-Q before arriving, the hospital cannot bill you for that device.

Three structural factors explain the gap between a $289 GoodRx price for Auvi-Q and a multi-thousand-dollar emergency bill. First, hospital acquisition costs for epinephrine are far below list prices, yet each hospital sets its own chargemaster markup. Second, emergency charges are bundled, which hides the per-drug amount on the bill. Third, patients rarely compare prices during a life-threatening reaction. If an emergency bill lists epinephrine above $500 or includes a separate device charge after you self-injected, request an itemized statement and use the Medical Bill Analyzer to compare each line against Medicare rates. Understanding both sides matters: a cheap, reliable auto-injector at home lowers the chance that a preventable delay turns into an expensive admission.

Patient Assistance Programs

Kaléo, the manufacturer of Auvi-Q, runs two affordability programs. Without any program, an uninsured patient faces a 2026 retail list price of about $762 to $872 per 2-pack, or about $360 through Kaléo's direct-delivery specialty pharmacy. The AUVI-Q Support Copay Program lowers the cost to $35 or less for commercially insured patients. The Kaléo Patient Assistance Program (a patient assistance program for uninsured US residents) supplies Auvi-Q at no cost when household income is under 250 percent of the federal poverty level, confirmed by the most recent W2 form, per the application effective October 10, 2025. Answering the question 'I have no insurance, what does the program get me?': $0 for eligible households, versus $289 to $872 at the counter.

Medicare Part D

Medicare Part D covers Auvi-Q only if a plan places it on its formulary, and coverage is less predictable than for generic epinephrine. Many plans prefer a generic epinephrine auto-injector on a lower formulary tier and place Auvi-Q on a non-preferred tier, exclude it, or require prior authorization. Check your plan's formulary before the 2026 plan year or during any special enrollment period, and ask your allergist to file a formulary exception request if Auvi-Q is medically necessary, such as for a patient who cannot reliably use a needle-forward device. In 2026 your total out-of-pocket Part D spending is capped at $2,100 under the Inflation Reduction Act of 2022, and the standard deductible is up to $615.

Patients with Medicare cannot use Kaléo's manufacturer coupon or copay program, and cash purchases made with a discount card generally do not count toward the $2,100 cap because they bypass the plan. Comparing the two is worthwhile: a $289 GoodRx price for one Auvi-Q 2-pack may be less than a plan's non-preferred-tier copay before the deductible is met, but it also will not build progress toward the cap. Medicare Extra Help (Low-Income Subsidy) can reduce Part D premiums, deductibles, and copays for eligible enrollees. Medicare Part B may pay only for physician-administered epinephrine (HCPCS J0171) in a clinic or emergency setting, at 20 percent coinsurance after the 2026 Part B deductible of $283.

Common Auvi-Q Billing Errors

If your Auvi-Q bill is higher than expected, check these common issues before paying in 2026:

• Generic substituted or refused: a pharmacist cannot swap a generic EpiPen-style device for an Auvi-Q prescription without a new prescription. If your plan denies Auvi-Q for a generic, the fix is a prescriber-supported exception or a new prescription, not a pharmacy substitution.
• Copay program not applied: commercially insured patients must enroll in the AUVI-Q Support Copay Program before the fill, and cash discount cards cannot be combined with it. Ask the pharmacy to reprocess the claim with the program details, or call 844-357-3968 with offer questions.
• Wrong strength dispensed: Auvi-Q comes in 0.3 mg, 0.15 mg, and 0.1 mg, with different NDCs. Confirm the strength matches the prescription and the patient's current weight, since a wrong strength can cause claim rejections and a clinical risk.
• Prior authorization missed: plans that cover Auvi-Q often require prior authorization and documentation of why a preferred device is unsuitable. A rejected claim at the counter is often a missing prior authorization, not a true exclusion.
• Emergency department billing the device after you self-injected: if you used your own Auvi-Q, a hospital should not also bill a drug charge for that dose. Request an itemized bill and dispute duplicate epinephrine lines.

Frequently Asked Questions